Detalhe da pesquisa
1.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol
; 204(4): 1293-1299, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263627
2.
Overexpressing Vitamin C Defective 2 reduces fertility and alters Ca2+ signals in Arabidopsis pollen.
Plant Physiol
; 191(4): 2276-2287, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708195
3.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
4.
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
Ann Hematol
; 103(1): 251-258, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851073
5.
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Eur J Haematol
; 112(4): 538-546, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38044594
6.
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Eur J Haematol
; 112(6): 975-983, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38382632
7.
Deficiencies in cluster-2 ALA lipid flippases result in salicylic acid-dependent growth reductions.
Physiol Plant
; 176(2): e14228, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413387
8.
Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy.
J Oncol Pharm Pract
; 30(1): 151-158, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37097891
9.
Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma.
J Oncol Pharm Pract
; : 10781552231224361, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38166529
10.
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
J Oncol Pharm Pract
; 29(3): 722-726, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36775940
11.
Dynamic membranes: the multiple roles of P4 and P5 ATPases.
Plant Physiol
; 185(3): 619-631, 2021 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822217
12.
Arabidopsis Ca2+-ATPases 1, 2, and 7 in the endoplasmic reticulum contribute to growth and pollen fitness.
Plant Physiol
; 185(4): 1966-1985, 2021 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33575795
13.
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
Ann Hematol
; 101(12): 2601-2610, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214853
14.
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
J Oncol Pharm Pract
; 28(3): 686-690, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35037773
15.
The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
J Oncol Pharm Pract
; 28(4): 960-968, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35006032
16.
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.
J Oncol Pharm Pract
; 28(7): 1613-1616, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35790453
17.
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies.
Blood
; 141(2): 200-203, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332185
18.
Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients.
J Med Virol
; 95(8): e29027, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548241
19.
The incidence and characteristics of VTE within 100 days of CAR T-cell therapy.
Ann Hematol
; 102(3): 683-685, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36658372
20.
Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy.
Ann Hematol
; 102(2): 461-462, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385650